تهدف هذه الدراسة إلى تقصي أهمية مقايسة المعلم IGFBP-3
البروتين الرابط لعامل النمو الشبيه بالأنسولين 3 لدى أطفال
سوريين مصابين بابيضاض دم لمفاوي حاد لاستخدامه كمؤشر
إضافي في تشخيص المرض و متابعة تطوره.
This study aimed to
investigate the validity of measuring IGFBP-3 in the serum of
Syrian children with acute lymphoblastic leukemia (ALL) as
additional markers in diagnosis and follow-up of the disease.
References used
Bethesda, SEER Cancer Statistic Review, National Cancer Institute. 1973، 467، 2000
R. Wäsch, W.D., M. Lübbert, Hematological Neoplasia, in Concise Manual of Hematology and Oncology, M.E. D.P.Berger, H.Henb, R. Mertelsmann ,Editor, Springer: Springer-Verlag، 400-529،Berlin Heidelberg 2008
Corrigan JJ, F.S., Guidelines for pediatric cancer centers. Pediatrics. 113:182-183، 2004
Chemotherapy causes neutropenia and increase susceptibility to infections. Morbidity and mortality due to infections remain serious problem in children with cancer. Decreased serum levels of Mannose-binding lectin ( MBL) may represent a risk factor f
In contrast to adaptive immunity and to certain components of innate immunity, only little is known on the influence of the complement system on cancer suppression and promotion . The lectin pathway of complement activation is an important part of in
Our study aimed to evaluating significance of survivin as a
prognostic marker of relapse in children with acute lymphoblastic
leukemia. The study included 46 child (30 males, 16 females): 24
child with ALL at 35 day from BFM 95 Protocol and 22 rel
The study aimed to identify the levels of IGF-1 growth factor in patients with non-insulin-dependent diabetes mellitus, where the levels of IGF-1 growth factor and its relationship with some important laboratory parameters such as (fasting blood gluc
Relapse of acute lymphoblastic leukemia (ALL) in the central nervous system
(CNS) in adults is considered a poor prognostic feature. Few reports have analyzed this issue. The
objective of this study was to estimate the experience with CNS recurrence in adult patients with ALL,
then to choose the best therapy.